|
gptkbp:instanceOf
|
vaccine
|
|
gptkbp:administeredBy
|
intramuscular injection
|
|
gptkbp:age
|
6 months and older
|
|
gptkbp:alsoKnownAs
|
gptkb:BNT162b2
gptkb:Comirnaty
|
|
gptkbp:annualRevenue2021
|
$36.8 billion (Pfizer COVID-19 vaccine sales)
|
|
gptkbp:approvedBy
|
gptkb:World_Health_Organization
gptkb:European_Medicines_Agency
gptkb:U.S._Food_and_Drug_Administration
|
|
gptkbp:boosters
|
Yes
|
|
gptkbp:clinicalTrialPhase
|
July-November 2020
|
|
gptkbp:contains
|
sucrose
salts
lipid nanoparticles
buffer solution
mRNA encoding SARS-CoV-2 spike protein
|
|
gptkbp:developedBy
|
gptkb:Pfizer
gptkb:BioNTech
|
|
gptkbp:distributor
|
gptkb:Fosun_Pharma_(China)
|
|
gptkbp:effect
|
~95% against symptomatic COVID-19 (original strain)
|
|
gptkbp:emergencyServices
|
December 2020
|
|
gptkbp:firstCountryAuthorized
|
gptkb:United_Kingdom
|
|
gptkbp:firstDoseAdministered
|
December 8, 2020
|
|
gptkbp:form
|
2 doses, 3 weeks apart
|
|
gptkbp:fullApprovalDate
|
August 2021
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Pfizer-BioNTech
|
|
gptkbp:indication
|
Prevention of COVID-19
|
|
gptkbp:manufacturer
|
gptkb:Belgium
gptkb:Germany
gptkb:United_States
|
|
gptkbp:marketedAs
|
gptkb:Pfizer
gptkb:BioNTech
|
|
gptkbp:patent
|
gptkb:Pfizer
gptkb:BioNTech
|
|
gptkbp:sideEffect
|
fever
fatigue
headache
muscle pain
chills
injection site pain
|
|
gptkbp:storage
|
-70°C
|
|
gptkbp:vaccineType
|
vaccine
|
|
gptkbp:variantAdaptedVersions
|
Omicron-adapted vaccine
|
|
gptkbp:website
|
https://www.comirnatyglobal.com/
https://www.pfizer.com/science/coronavirus/vaccine
|
|
gptkbp:WHOEmergencyUseListing
|
December 31, 2020
|
|
gptkbp:bfsParent
|
gptkb:COVID-19
|
|
gptkbp:bfsLayer
|
4
|